Lunsumio (mosunetuzumab-axgb) — Medica
Relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
Initial criteria
- Patient is age ≥ 18 years
- Patient has received ≥ two lines of systemic therapy
- Medication is prescribed by or in consultation with an oncologist
Approval duration
1 year